KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. (Q37693609)
Jump to navigation
Jump to search
scientific article published on 04 February 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. |
scientific article published on 04 February 2013 |
Statements
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia (English)
Anthony Letai
Takaomi Sanda
Julia Etchin
Bonnie T Le
Amanda L Christie
Dilara McCauley
Scott J Rodig
Michael Kauffman
Sharon Shacham
Richard Stone
4 February 2013
1 reference